HLX 54
Alternative Names: HLX-54Latest Information Update: 05 Feb 2021
At a glance
- Originator Shanghai Henlius Biotech
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Triple negative breast cancer
Most Recent Events
- 22 Jan 2021 Preclinical trials in Triple negative Breast cancer in China (unspecified route) before January 2021 (Shanghai Henlius Biotech pipeline, January 2021)